Non Hodgkin Lymphoma Clinical Trial
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin’s Lymphoma (NHL)
Summary
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
Eligibility Criteria
Inclusion Criteria:
CD20+ follicular B-cell non-hodgkin's lymphoma with at least 1 site of measurable disease.
Previous treatment with 1 to 4 prior chemotherapy regimens
ECOG performance status of greater than or equal to 2
Life expectancy of greater than 18 weeks
Meet safety lab requirements and organ function tests
Exclusion Criteria:
Prior treatment with rituximab or IL-2
Prior radioimmunotherapy including Zevalin or Bexxar
5 or more prior chemotherapy regimens
Clinically significant cardiac disease, lung dysfunction, autoimmune disease, thyroid disease, active infection, unstable psychiatric condition, or HIV infection.
History of allogenic bone marrow transplant
Female subjects that are pregnant or breast feeding
Immunosuppressive therapy including corticosteroids or investigational agents within 4 weeks prior to the planned start of study treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Buffalo New York, 14263, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.